
Qualitek Labs (QLL) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
1.6B
Total Liabilities
651.4M
Shareholders Equity
927.8M
Debt to Equity
0.70
Cash Flow Metrics
Revenue & Profitability Trend
Qualitek Labs Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 702.3M | 291.8M | 191.4M | 120.1M | 63.5M |
Cost of Goods Sold | 102.0M | 57.8M | 42.5M | 18.9M | 15.1M |
Gross Profit | 600.2M | 234.1M | 148.9M | 101.2M | 48.5M |
Gross Margin % | 85.5% | 80.2% | 77.8% | 84.2% | 76.3% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | - | 11.1M | 13.3M | 6.0M |
Other Operating Expenses | 196.5M | 93.1M | 59.4M | 27.3M | 14.5M |
Total Operating Expenses | 196.5M | 93.1M | 70.5M | 40.6M | 20.5M |
Operating Income | 119.9M | 66.5M | 44.5M | 7.8M | 4.0M |
Operating Margin % | 17.1% | 22.8% | 23.3% | 6.5% | 6.3% |
Non-Operating Items | |||||
Interest Income | - | - | 584.0K | 112.0K | 0 |
Interest Expense | 20.9M | 9.1M | 6.9M | 2.8M | 70.0K |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 104.2M | 58.2M | 39.4M | 4.9M | 3.9M |
Income Tax | 27.3M | 15.2M | 9.9M | 642.0K | 2.3M |
Effective Tax Rate % | 26.2% | 26.0% | 25.3% | 13.2% | 60.4% |
Net Income | 76.8M | 43.1M | 29.4M | 4.2M | 1.5M |
Net Margin % | 10.9% | 14.8% | 15.4% | 3.5% | 2.4% |
Key Metrics | |||||
EBITDA | 167.6M | 81.3M | 55.1M | 12.9M | 7.4M |
EPS (Basic) | - | ₹7.46 | ₹3.99 | ₹0.57 | ₹0.21 |
EPS (Diluted) | - | ₹7.46 | ₹3.99 | ₹0.57 | ₹0.21 |
Basic Shares Outstanding | - | 5773861 | 7371900 | 7371900 | 7371900 |
Diluted Shares Outstanding | - | 5773861 | 7371900 | 7371900 | 7371900 |
Income Statement Trend
Qualitek Labs Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 51.7M | 17.7M | 3.5M | 279.0K | 1.4M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 288.6M | 78.5M | 58.3M | 22.0M | 12.0M |
Inventory | 26.5M | - | - | - | - |
Other Current Assets | 8.2M | 2.0M | - | - | 1.0K |
Total Current Assets | 426.1M | 117.1M | 85.9M | 66.9M | 25.4M |
Non-Current Assets | |||||
Property, Plant & Equipment | 590.0M | 295.1M | - | - | - |
Goodwill | 663.6M | - | - | - | - |
Intangible Assets | 2.9M | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 46.9M | 16.0M | -1.0K | -1.0K | -2.0K |
Total Non-Current Assets | 1.2B | 388.8M | 309.7M | 143.3M | 117.9M |
Total Assets | 1.6B | 505.9M | 395.6M | 210.2M | 143.3M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 72.8M | 23.8M | 36.7M | 15.7M | 23.8M |
Short-term Debt | 191.2M | 20.8M | 131.1M | 171.5M | 109.7M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 55.9M | 23.2M | 1.0K | 6.7M | 8.4M |
Total Current Liabilities | 325.8M | 68.8M | 186.9M | 198.7M | 146.0M |
Non-Current Liabilities | |||||
Long-term Debt | 308.6M | 101.7M | 103.4M | 2.0M | 2.5M |
Deferred Tax Liabilities | 7.4M | 8.6M | 5.9M | 391.0K | 58.0K |
Other Non-Current Liabilities | -1.0K | - | -1.0K | - | - |
Total Non-Current Liabilities | 325.6M | 112.6M | 110.0M | 2.7M | 2.7M |
Total Liabilities | 651.4M | 181.4M | 296.9M | 201.4M | 148.7M |
Equity | |||||
Common Stock | 99.8M | 73.7M | 54.1M | 4.6M | 100.0K |
Retained Earnings | - | - | 38.7M | -1.2M | -5.4M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 927.8M | 324.5M | 98.7M | 8.8M | -5.3M |
Key Metrics | |||||
Total Debt | 499.8M | 122.5M | 234.5M | 173.5M | 112.2M |
Working Capital | 100.2M | 48.3M | -101.0M | -131.9M | -120.6M |
Balance Sheet Composition
Qualitek Labs Cash Flow Statement From 2021 to 2024
Metric | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Operating Activities | ||||
Net Income | 58.2M | 39.4M | 4.6M | 3.9M |
Depreciation & Amortization | - | - | - | - |
Stock-Based Compensation | - | - | - | - |
Working Capital Changes | -14.1M | 5.2M | -44.2M | -1.8M |
Operating Cash Flow | 53.2M | 50.3M | -36.9M | 2.2M |
Investing Activities | ||||
Capital Expenditures | -100.0M | -173.2M | -17.7M | -60.6M |
Acquisitions | -86.7M | -148.5M | - | 30.0K |
Investment Purchases | - | - | - | - |
Investment Sales | - | - | - | - |
Investing Cash Flow | -186.7M | -321.7M | -17.7M | -60.6M |
Financing Activities | ||||
Share Repurchases | - | - | - | - |
Dividends Paid | - | - | - | - |
Debt Issuance | - | 101.4M | 0 | - |
Debt Repayment | - | 0 | -519.0K | -61.4M |
Financing Cash Flow | 72.2M | 111.6M | 71.2M | 48.3M |
Free Cash Flow | -48.0M | -100.6M | -69.1M | -47.1M |
Net Change in Cash | -61.3M | -159.9M | 16.6M | -10.1M |
Cash Flow Trend
Qualitek Labs Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
45.40
Price to Book
3.29
Price to Sales
4.56
Profitability Ratios
Profit Margin
8.97%
Operating Margin
20.77%
Return on Equity
12.27%
Return on Assets
7.19%
Financial Health
Current Ratio
1.31
Debt to Equity
37.74
Per Share Data
EPS (TTM)
₹7.07
Book Value per Share
₹97.54
Revenue per Share
₹78.91
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
qll | 3.2B | 45.40 | 3.29 | 12.27% | 8.97% | 37.74 |
Dr. Lal PathLabs | 288.0B | 55.99 | 13.24 | 22.08% | 20.29% | 7.14 |
Syngene | 268.2B | 52.80 | 5.68 | 10.50% | 13.61% | 12.23 |
Vimta Labs | 31.5B | 44.49 | 8.30 | 17.78% | 19.93% | 2.25 |
Krsnaa Diagnostics | 26.8B | 33.93 | 3.02 | 8.79% | 10.84% | 23.06 |
Suraksha Diagnostic | 16.6B | 49.97 | 7.86 | 15.14% | 12.62% | 42.28 |
Financial data is updated regularly. All figures are in the company's reporting currency.